AMGN

Amgen Stock Price

225.00
2.96 (1.33%)
Upgrade to Real-Time
Afterhours (Closed)
225.00
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Amgen Inc AMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
2.96 1.33% 225.00 20:00:00
Open Price Low Price High Price Close Price Previous Close
224.88 222.72 225.78 225.08 222.04
Bid Price Ask Price Spread News
223.30 229.00 5.70 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
36,482 3,052,828 $ 224.66 $ 685,846,476 2,505,600 177.05 - 264.97
Last Trade Time Type Quantity Stock Price Currency
19:59:26 1 $ 225.00 USD

Amgen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 130.99B 582.17M 580.77M $ 23.36B $ 6.84B 12.89 18.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 5.80 2.58% - -

more financials information »

Amgen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week222.45226.21218.92221.653,082,6372.551.15%
1 Month221.78245.84218.53229.132,632,7453.221.45%
3 Months246.63258.505210.28236.232,588,957-21.63-8.77%
6 Months228.89264.97210.28239.632,576,438-3.89-1.7%
1 Year234.54264.97177.05229.802,694,944-9.54-4.07%
3 Years174.16264.97163.31201.522,907,30050.8429.19%
5 Years162.71264.97133.64185.262,946,63862.2938.28%

Amgen Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).


Your Recent History
NASDAQ
AMGN
Amgen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.